DRTS
HealthcareAlpha Tau Medical Ltd. · Biotechnology · $880M
What is Alpha Tau Medical Ltd.?
Alpha Tau Medical is a clinical-stage oncology company developing a novel radiation therapy platform for solid tumors. Headquartered in Jerusalem, Israel, it operates primarily in the United States and Israel.
Alpha Tau Medical develops its proprietary Alpha DaRT technology — a diffusing alpha-emitters radiation therapy — designed to treat solid cancers. The platform is being evaluated in clinical trials across skin, oral, pancreatic, and breast cancers, with preclinical work extending to glioblastoma, lung cancer, and liver cancer. As a pre-revenue clinical-stage company, it does not yet generate commercial sales.
The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
- Alpha DaRT radiation therapy platform
- Clinical trials in skin, oral, pancreatic, and breast cancers
- Preclinical research in glioblastoma, lung, and hepatic cancers
Is DRTS a Good Stock to Buy?
UQS Score rates DRTS as Poor overall, reflecting the early-stage nature of the business across most evaluated dimensions.
The Risk pillar stands out as the relative bright spot in DRTS's profile, suggesting the company's near-term financial stability is comparatively better managed than its other fundamentals might imply for a clinical-stage firm.
Quality, Moat, and Growth all register as Weak, consistent with a pre-revenue company that has yet to establish a commercial footprint or durable competitive position. Valuation is rated Elevated, adding further caution.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does DRTS pay dividends?
No — Alpha Tau Medical Ltd. does not currently pay a dividend.
Alpha Tau Medical does not pay a dividend. This is typical for clinical-stage biotech companies, which prioritize deploying capital into research, clinical trials, and regulatory development rather than returning cash to shareholders. Income-focused investors should factor this into their assessment.
When does DRTS report earnings?
Alpha Tau Medical reports financial results on a quarterly cadence, as is standard for US-listed equities.
As a clinical-stage company, DRTS does not yet report commercial revenues. Quarterly updates tend to focus on cash runway, trial progress, and operating expenses rather than top-line growth.
For the most recent quarter's results, visit Alpha Tau Medical's investor relations page directly.
DRTS Price History
-18.0% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Alpha Tau Medical Ltd.?
Based on Alpha Tau Medical Ltd.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
DRTS Long-term Outlook
The fundamental outlook for DRTS is shaped by its clinical-stage status. With Growth and Quality both rated Weak, near-term improvement in the UQS profile depends heavily on trial readouts and any path toward regulatory approval or commercialization. The Elevated Valuation rating suggests the market may already be pricing in optimistic scenarios, leaving limited margin for setbacks.
Growth drivers
- Positive clinical trial data across cancer indications
- Potential regulatory milestones in the US or Israel
- Expansion of Alpha DaRT into additional solid tumor types
Key risks
- Clinical trial failure or delays could significantly impair the business
- Elevated valuation leaves little room for negative news
- Ongoing cash consumption without commercial revenue creates funding dependency
DRTS vs Peers
Alpha Tau Medical operates in a competitive clinical-stage landscape alongside other development-stage biotech companies pursuing novel therapeutic platforms.
Arvinas focuses on targeted protein degradation via its PROTAC platform, a distinct mechanism from Alpha Tau's radiation-based approach.
Bright Minds targets neurological and psychiatric disorders, operating in a different therapeutic area than Alpha Tau's oncology focus.
Prime Medicine develops prime editing gene therapies, representing a genomic approach that contrasts with Alpha Tau's radiation therapy platform.
Frequently Asked Questions
What does Alpha Tau Medical do?
Alpha Tau Medical develops a radiation therapy technology called Alpha DaRT, which uses diffusing alpha-emitters to target solid tumors. The platform is being studied in clinical trials for cancers including skin, oral, pancreatic, and breast cancer, with additional preclinical work underway in other tumor types.
Does DRTS pay dividends?
No, DRTS does not pay a dividend. As a clinical-stage company with no commercial revenue, Alpha Tau Medical reinvests its available capital into research and clinical development rather than shareholder distributions.
When does DRTS report earnings?
Alpha Tau Medical reports on a quarterly cadence standard for US-listed companies. Because it is pre-revenue, updates focus on trial progress and cash position rather than sales figures. Check the company's investor relations page for the latest schedule.
Is DRTS a good stock to buy?
UQS Score rates DRTS as Poor overall. Quality, Moat, and Growth are all Weak, while Valuation is Elevated — a combination that warrants careful consideration. The Risk pillar is the relative strength. The full pillar breakdown is available to UQS Pro members.
Is DRTS overvalued?
UQS Score rates DRTS's Valuation as Elevated, meaning the current market pricing appears high relative to the company's fundamental profile. For a pre-revenue clinical-stage company, this can reflect speculative premium around future trial outcomes rather than current business performance.
How does DRTS compare to its competitors?
DRTS operates in the clinical-stage biotech space alongside companies like Arvinas, Bright Minds Biosciences, and Prime Medicine. Each pursues distinct therapeutic platforms and indications, making direct comparison complex. UQS Pro members can view side-by-side pillar scores for a structured comparison.
What is DRTS's market cap bracket?
Alpha Tau Medical is classified as a small-cap company. This places it in a segment of the market that typically carries higher volatility and liquidity risk compared to large- or mega-cap peers, which is particularly relevant for clinical-stage biotech names.
Who founded Alpha Tau Medical?
Alpha Tau Medical was founded based on research originating from Hebrew University of Jerusalem. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel. For detailed founding history, the company's official website and public filings are the most reliable sources.
Is DRTS a long-term quality investment?
As a long-term quality indicator, UQS Score currently rates DRTS as Poor. Weak scores across Quality, Moat, and Growth suggest the company has not yet established the durable fundamentals typically associated with long-term compounders. Clinical progress could change this profile over time.
What is the main competitive advantage of Alpha Tau Medical?
Alpha Tau Medical's potential advantage lies in the proprietary nature of its Alpha DaRT technology, which uses a distinct physical mechanism — diffusing alpha radiation — to attack solid tumors. If clinical data validates the approach, this platform differentiation could form the basis of a future moat.
Unlock Full DRTS Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar scores for DRTS
- ✓Access full financial metrics and trend data
- ✓Compare DRTS side-by-side with clinical-stage peers
- ✓See the complete risk and valuation breakdown
- ✓Get alerts when DRTS's UQS profile changes
Pro Analysis
DRTS — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 18.7 | 0.0 | 25.0 | 0.3 | 82.4 | 0.0 | -2.4 |
| Apr 22, 2026 | 21.1 | 14.1 | 25.0 | 0.3 | 74.8 | 0.0 | 0.0 |
| Apr 2, 2026 | 21.1 | 14.1 | 25.0 | 0.4 | 74.8 | 0.0 | — |
DRTS — Pillar Breakdown
Quality
— 0.0/100 (25%)Alpha Tau Medical Ltd. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.3/100 (20%)Alpha Tau Medical Ltd. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 82.4/100 (15%)Alpha Tau Medical Ltd. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Alpha Tau Medical Ltd. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 25/100 (25%)Alpha Tau Medical Ltd. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for DRTS.
Score Composition
Financial Data
More Stock Analysis
How is the DRTS UQS Score Calculated?
The UQS (Unified Quality Score) for Alpha Tau Medical Ltd. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Alpha Tau Medical Ltd.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Alpha Tau Medical Ltd. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.